These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 10733410)

  • 1. Hepatitis C virus, the E2 envelope protein, and alpha-interferon resistance.
    Abid K; Quadri R; Negro F
    Science; 2000 Mar; 287(5458):1555. PubMed ID: 10733410
    [No Abstract]   [Full Text] [Related]  

  • 2. Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein.
    Taylor DR; Shi ST; Romano PR; Barber GN; Lai MM
    Science; 1999 Jul; 285(5424):107-10. PubMed ID: 10390359
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The protein kinase-interacting domain in the hepatitis C virus envelope glycoprotein-2 gene is highly conserved in genotype 1-infected patients treated with interferon.
    Polyak SJ; Nousbaum JB; Larson AM; Cotler S; Carithers RL; Gretch DR
    J Infect Dis; 2000 Aug; 182(2):397-404. PubMed ID: 10915068
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of amino acid sequence in the PKR-eIF2 phosphorylation homology domain and response to interferon therapy.
    Chayama K; Suzuki F; Tsubota A; Kobayashi M; Arase Y; Saitoh S; Suzuki Y; Murashima N; Ikeda K; Takahashi N; Kinoshita M; Kumada H
    Hepatology; 2000 Nov; 32(5):1138-44. PubMed ID: 11050067
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sequence analysis of PePHD within HCV E2 region and correlation with resistance of interferon therapy in Japanese patients infected with HCV genotypes 2a and 2b.
    Saito T; Ito T; Ishiko H; Yonaha M; Morikawa K; Miyokawa A; Mitamura K
    Am J Gastroenterol; 2003 Jun; 98(6):1377-83. PubMed ID: 12818284
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The amino acid sequence of the PKR-eIF2alpha phosphorylation homology domain of hepatitis C virus envelope 2 protein and response to interferon-alpha.
    Cochrane A; Orr A; Shaw ML; Mills PR; McCruden EA
    J Infect Dis; 2000 Nov; 182(5):1515-8. PubMed ID: 11023475
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of the PKR-eIF2alpha phosphorylation homology domain (PePHD) of hepatitis C virus genotype 1 in HIV-coinfected patients by ultra-deep pyrosequencing and its relationship to responses to pegylated interferon-ribavirin treatment.
    Bolcic F; Sede M; Moretti F; Westergaard G; Vazquez M; Laufer N; Quarleri J
    Arch Virol; 2012 Apr; 157(4):703-11. PubMed ID: 22270759
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The mechanisms of hepatitis C virus resistance to interferon].
    Kmieciak D
    Postepy Biochem; 2005; 51(1):22-7. PubMed ID: 16209338
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Positional effect of phosphorylation sites 266 and 267 in the cytoplasmic domain of the E2 protein of hepatitis C virus 3a genotype: interferon resistance analysis via sequence alignment.
    Rafique S; Idrees M; Ilyas M; Hussain A; Ali M; Ali L; Butt S; Afzal S; Ur Rehman I; Saleem S
    Virol J; 2011 May; 8():204. PubMed ID: 21545731
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutations within the hepatitis C virus genotype 1b E2-PePHD domain do not correlate with treatment outcome.
    Gaudy C; Lambelé M; Moreau A; Veillon P; Lunel F; Goudeau A
    J Clin Microbiol; 2005 Feb; 43(2):750-4. PubMed ID: 15695675
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protein synthesis and endoplasmic reticulum stress can be modulated by the hepatitis C virus envelope protein E2 through the eukaryotic initiation factor 2alpha kinase PERK.
    Pavio N; Romano PR; Graczyk TM; Feinstone SM; Taylor DR
    J Virol; 2003 Mar; 77(6):3578-85. PubMed ID: 12610133
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutations in carboxy-terminal part of E2 including PKR/eIF2alpha phosphorylation homology domain and interferon sensitivity determining region of nonstructural 5A of hepatitis C virus 1b: their correlation with response to interferon monotherapy and viral load.
    Ukai K; Ishigami M; Yoshioka K; Kawabe N; Katano Y; Hayashi K; Honda T; Yano M; Goto H
    World J Gastroenterol; 2006 Jun; 12(23):3722-8. PubMed ID: 16773689
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evading the interferon response: hepatitis C virus and the interferon-induced protein kinase, PKR.
    Korth MJ; Katze MG
    Curr Top Microbiol Immunol; 2000; 242():197-224. PubMed ID: 10592662
    [No Abstract]   [Full Text] [Related]  

  • 14. GB virus type C NS5A sequence polymorphisms: association with interferon susceptibility and inhibition of PKR-mediated eIF2alpha phosphorylation.
    Xiang J; Martinez-Smith C; Gale M; Chang Q; Labrecque DR; Schmidt WN; Stapleton JT
    J Interferon Cytokine Res; 2005 May; 25(5):261-70. PubMed ID: 15871663
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatitis C virus envelope protein E2 does not inhibit PKR by simple competition with autophosphorylation sites in the RNA-binding domain.
    Taylor DR; Tian B; Romano PR; Hinnebusch AG; Lai MM; Mathews MB
    J Virol; 2001 Feb; 75(3):1265-73. PubMed ID: 11152499
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cyclophilin inhibitors reduce phosphorylation of RNA-dependent protein kinase to restore expression of IFN-stimulated genes in HCV-infected cells.
    Daito T; Watashi K; Sluder A; Ohashi H; Nakajima S; Borroto-Esoda K; Fujita T; Wakita T
    Gastroenterology; 2014 Aug; 147(2):463-72. PubMed ID: 24786893
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PKR protein kinase is activated by hepatitis C virus and inhibits viral replication through translational control.
    Kang JI; Kwon SN; Park SH; Kim YK; Choi SY; Kim JP; Ahn BY
    Virus Res; 2009 Jun; 142(1-2):51-6. PubMed ID: 19189853
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Understanding the molecular mechanism(s) of hepatitis C virus (HCV) induced interferon resistance.
    Qashqari H; Al-Mars A; Chaudhary A; Abuzenadah A; Damanhouri G; Alqahtani M; Mahmoud M; El Sayed Zaki M; Fatima K; Qadri I
    Infect Genet Evol; 2013 Oct; 19():113-9. PubMed ID: 23831932
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pretreatment virus load and multiple amino acid substitutions in the interferon sensitivity-determining region predict the outcome of interferon treatment in patients with chronic genotype 1b hepatitis C virus infection.
    Chayama K; Tsubota A; Kobayashi M; Okamoto K; Hashimoto M; Miyano Y; Koike H; Kobayashi M; Koida I; Arase Y; Saitoh S; Suzuki Y; Murashima N; Ikeda K; Kumada H
    Hepatology; 1997 Mar; 25(3):745-9. PubMed ID: 9049229
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutations in the interferon sensitivity-determining region of hepatitis C virus genotype 2a correlate with response to pegylated-interferon-alpha 2a monotherapy.
    Hayashi K; Katano Y; Honda T; Ishigami M; Itoh A; Hirooka Y; Nakano I; Urano F; Yoshioka K; Toyoda H; Kumada T; Goto H
    J Med Virol; 2009 Mar; 81(3):459-66. PubMed ID: 19152412
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.